{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:26:48Z","timestamp":1781659608463,"version":"3.54.5"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004022","name":"Jenny ja Antti Wihurin Rahasto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.pharmthera.2020.107620","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T12:57:15Z","timestamp":1593176235000},"page":"107620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Cyclodextrins: Potential therapeutics against atherosclerosis"],"prefix":"10.1016","volume":"214","author":[{"given":"Maryam","family":"Mahjoubin-Tehran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petri T.","family":"Kovanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suowen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannaz","family":"Jamialahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2020.107620_bb0005","doi-asserted-by":"crossref","first-page":"19316","DOI":"10.1073\/pnas.0910916106","article-title":"Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-pick type C cells","volume":"106","author":"Abi-Mosleh","year":"2009","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0010","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-016-0284-6","article-title":"Randomized double blind clinical trial on the effect of oral alpha-cyclodextrin on serum lipids","volume":"15","author":"Amar","year":"2016","journal-title":"Lipids in Health and Disease"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejps.2016.04.037","article-title":"Effects of cyclodextrins on the structure of LDL and its susceptibility to copper-induced oxidation","volume":"91","author":"Ao","year":"2016","journal-title":"European Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0020","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1248\/bpb.b16-00047","article-title":"Methyl-\u03b2-cyclodextrin impairs the monocyte-adhering ability of endothelial cells by down-regulating adhesion molecules and caveolae and reorganizing the actin cytoskeleton","volume":"39","author":"Ao","year":"2016","journal-title":"Biological and Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0025","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s10311-019-00878-w","article-title":"Cyclodextrin-based delivery systems for dietary pharmaceuticals","volume":"17","author":"Arora","year":"2019","journal-title":"Environmental Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0030","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1172\/JCI119223","article-title":"Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells","volume":"99","author":"Atger","year":"1997","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0035","first-page":"389","article-title":"Inflammation and its resolution in atherosclerosis: Mediators and therapeutic opportunities","volume":"16","author":"B\u00e4ck","year":"2019","journal-title":"Nature Reviews Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0040","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.4049\/jimmunol.1700302","article-title":"Cyclodextrin reduces cholesterol crystal-induced inflammation by modulating complement activation","volume":"199","author":"Bakke","year":"2017","journal-title":"Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0045","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12324","article-title":"Effects of alpha-cyclodextrin on cholesterol control and compound K on glycaemic control in people with pre-diabetes: Protocol for a phase III randomized controlled trial","volume":"9","author":"Bessell","year":"2019","journal-title":"Clinical obesity"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0050","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European atherosclerosis society consensus panel","author":"Bor\u00e9n","year":"2020","journal-title":"European Heart Journal."},{"key":"10.1016\/j.pharmthera.2020.107620_bb0055","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1126\/science.6261329","article-title":"Regulation of plasma cholesterol by lipoprotein receptors","volume":"212","author":"Brown","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0060","first-page":"68","article-title":"Cyclodextrin inclusion complex to enhance solubility of poorly water soluble drugs: A review","volume":"4","author":"Chaudhary","year":"2013","journal-title":"International Journal of Pharmaceutical Sciences and Research"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0065","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S0022-2275(20)34940-3","article-title":"Use of cyclodextrins for manipulating cellular cholesterol content","volume":"38","author":"Christian","year":"1997","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0070","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fphys.2016.00185","article-title":"\u03b2-Cyclodextrins decrease cholesterol release and ABC-associated transporter expression in smooth muscle cells and aortic endothelial cells","volume":"7","author":"Coisne","year":"2016","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0075","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/oby.2010.280","article-title":"The beneficial effects \u03b1-Cyclodextrin on blood lipids and weight loss in healthy humans","volume":"19","author":"Comerford","year":"2011","journal-title":"Obesity"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/10717540050120205","article-title":"Apolipoprotein A-I, phospholipid vesicles, and cyclodextrins as potential anti-atherosclerotic drugs: Delivery, pharmacokinetics, and efficacy","volume":"7","author":"Dass","year":"2000","journal-title":"Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0085","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nrd1576","article-title":"Cyclodextrin-based pharmaceutics: Past, present and future","volume":"3","author":"Davis","year":"2004","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0090","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0095","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0026-0495(95)90265-1","article-title":"Effect of cyclodextrin on plasma lipids and cholesterol metabolism in the rat","volume":"44","author":"Favier","year":"1995","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10311-018-0807-7","article-title":"Applications of steroid drugs entrapped in cyclodextrins","volume":"17","author":"Fenyvesi","year":"2019","journal-title":"Environmental Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0105","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0110","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1021\/bi992125q","article-title":"Efflux of cholesterol from different cellular pools","volume":"39","author":"Haynes","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0115","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1161\/01.ATV.13.6.924","article-title":"Inhibition of smooth muscle cell proliferation and experimental angioplasty restenosis by \u03b2-cyclodextrin tetradecasulfate","volume":"13","author":"Herrmann","year":"1993","journal-title":"Arteriosclerosis and Thrombosis"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0120","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrm2336","article-title":"Cellular cholesterol trafficking and compartmentalization","volume":"9","author":"Ikonen","year":"2008","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0125","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/jps.2600810610","article-title":"Hydroxypropylcyclodextrins in parenteral use. II: Effects on transport and disposition of lipids in rabbit and humans","volume":"81","author":"Irie","year":"1992","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0130","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/eurheartj\/ehv653","article-title":"Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque","volume":"37","author":"Janoudi","year":"2016","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0135","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.metabol.2013.05.015","article-title":"The effect of \u03b1-Cyclodextrin on postprandial lipid and glycemic responses to a fat-containing meal","volume":"62","author":"Jarosz","year":"2013","journal-title":"Metabolism: Clinical and Experimental"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0140","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/01.ATV.19.8.1891","article-title":"Crystallization of free cholesterol in model macrophage foam cells","volume":"19","author":"Kellner-Weibel","year":"1999","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0145","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1021\/cr970012b","article-title":"Methods for selective modifications of cyclodextrins","volume":"98","author":"Khan","year":"1998","journal-title":"Chemical Reviews"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0155","doi-asserted-by":"crossref","first-page":"17250","DOI":"10.1074\/jbc.270.29.17250","article-title":"Cellular cholesterol efflux mediated by cyclodextrins","volume":"270","author":"Kilsdonk","year":"1995","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0160","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2019.12.021","article-title":"Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity","volume":"319","author":"Kim","year":"2019","journal-title":"The Journal of Controlled Release"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0165","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.bcp.2019.04.003","article-title":"Keep recycling going: New approaches to reduce LDL-C","volume":"164","author":"Klein-Szanto","year":"2019","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0170","doi-asserted-by":"crossref","first-page":"27450","DOI":"10.1074\/jbc.271.44.27450","article-title":"Hydroxypropyl-\u03b2-cyclodextrin-mediated efflux of 7-ketocholesterol from macrophage foam cells","volume":"271","author":"Kritharides","year":"1996","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0175","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ajpath.2017.09.019","article-title":"Extracellular lipids accumulate in human carotid arteries as distinct three-dimensional structures and have proinflammatory properties","volume":"188","author":"Lehti","year":"2018","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0180","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nature Reviews Disease Primers"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0185","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/ATVBAHA.118.310958","article-title":"Novel Antiatherosclerotic therapies","volume":"39","author":"Libby","year":"2019","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0190","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1073\/pnas.0810895106","article-title":"Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1\u2212\/\u2212 mouse","volume":"106","author":"Liu","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0195","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1194\/jlr.M200464-JLR200","article-title":"Cyclodextrins differentially mobilize free and esterified cholesterol from primary human foam cell macrophages","volume":"44","author":"Liu","year":"2003","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0200","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijpharm.2019.02.004","article-title":"Self-association of cyclodextrins and cyclodextrin complexes in aqueous solutions","volume":"560","author":"Loftsson","year":"2019","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002020","article-title":"Molecular mechanism of cyclodextrin mediated cholesterol extraction","volume":"7","author":"L\u00f3pez","year":"2011","journal-title":"PLoS Computational Biology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0210","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35025203","article-title":"Atherosclerosis","volume":"407","author":"Lusis","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0215","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0220","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.molliq.2018.04.098","article-title":"Investigation of the influence of \u03b2-cyclodextrin on cholesterol lodgement \u2014 A molecular dynamics simulation study","volume":"262","author":"Makie\u0142a","year":"2018","journal-title":"Journal of Molecular Liquids"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0225","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.vph.2015.04.008","article-title":"Treatment with KLEPTOSE\u00ae CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response","volume":"72","author":"Montecucco","year":"2015","journal-title":"Vascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0230","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/S0140-6736(17)31465-4","article-title":"Intrathecal 2-hydroxypropyl-\u03b2-cyclodextrin decreases neurological disease progression in Niemann-pick disease, type C1: A non-randomised, open-label, phase 1\u20132 trial","volume":"390","author":"Ory","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0235","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14656566.2019.1702970","article-title":"PCSK9 inhibitors for treating hypercholesterolemia","volume":"21","author":"Pasta","year":"2020","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0240","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1161\/CIRCULATIONAHA.118.035289","article-title":"Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine","volume":"137","author":"Patel","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0245","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1046\/j.1365-2796.2000.00655.x","article-title":"Modified LDL\u2013trigger of atherosclerosis and inflammation in the arterial intima","volume":"247","author":"Pentik\u00e4inen","year":"2000","journal-title":"Journal of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0250","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.atherosclerosis.2019.01.034","article-title":"Alpha-cyclodextrin inhibits cholesterol crystal-induced complement-mediated inflammation: A potential new compound for treatment of atherosclerosis","volume":"283","author":"Pilely","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0255","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/152786","article-title":"LOX-1, OxLDL, and atherosclerosis","volume":"2013","author":"Pirillo","year":"2013","journal-title":"Mediators of Inflammation"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: A novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajamaki","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0265","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCRESAHA.115.304666","article-title":"CD36-dependent 7-ketocholesterol accumulation in macrophages mediates progression of atherosclerosis in response to chronic air pollution exposure","volume":"115","author":"Rao","year":"2014","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0270","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.119.045256","article-title":"From CANTOS to CIRT to COLCOT to clinic: Will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents?","volume":"141","author":"Ridker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0275","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2020.107620_bb1000","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10557-013-6479-4","article-title":"New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: What can the clinician expect?","volume":"27","author":"Sahebkar","year":"2013","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201600804","article-title":"Dietary \u03b1-cyclodextrin reduces atherosclerosis and modifies gut flora in apolipoprotein E-deficient mice","volume":"61","author":"Sakurai","year":"2017","journal-title":"Molecular Nutrition and Food Research"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0285","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3390\/molecules23051161","article-title":"Solubility of cyclodextrins and drug\/cyclodextrin complexes","volume":"23","author":"Saokham","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0290","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/ni.2639","article-title":"CD36 coordinates activation of the NLRP3 inflammasome by facilitating the intracellular nucleation of soluble to particulate ligands in sterile inflammation","volume":"14","author":"Sheedy","year":"2013","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0295","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.237271","article-title":"High-density lipoprotein or cyclodextrin extraction of cholesterol from aggregated LDL reduces foam cell formation","volume":"132","author":"Singh","year":"2019","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0300","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: Impact on statin therapy\u2014European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0305","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1080\/21691401.2019.1617724","article-title":"DNA methylation abnormalities in atherosclerosis","volume":"47","author":"Tabaei","year":"2019","journal-title":"Artificial Cells, Nanomedicine and Biotechnology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0310","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0315","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1248\/cpb.52.900","article-title":"Design and evaluation of cyclodextrin-based drug formulation","volume":"52","author":"Uekama","year":"2004","journal-title":"Chemical and Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0320","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.drudis.2019.04.007","article-title":"Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: State of the art","volume":"24","author":"Vahdat Lasemi","year":"2019","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0325","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.metabol.2008.02.020","article-title":"Dietary \u03b1-cyclodextrin lowers low-density lipoprotein cholesterol and alters plasma fatty acid profile in low-density lipoprotein receptor knockout mice on a high-fat diet","volume":"57","author":"Wagner","year":"2008","journal-title":"Metabolism: Clinical and Experimental"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0330","doi-asserted-by":"crossref","first-page":"21056","DOI":"10.3390\/ijms160921056","article-title":"Weekly treatment of 2-hydroxypropyl-\u03b2-cyclodextrin improves intracellular cholesterol levels in LDL receptor knockout mice","volume":"16","author":"Walenbergh","year":"2015","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0335","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1124\/pr.118.017178","article-title":"Targeting foam cell formation in atherosclerosis: Therapeutic potential of natural products","volume":"71","author":"Wang","year":"2019","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0340","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/FJC.0000000000000660","article-title":"Cyclodextrin ameliorates the progression of atherosclerosis via increasing high-density lipoprotein cholesterol plasma levels and anti-inflammatory effects in rabbits","volume":"73","author":"Wang","year":"2019","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0345","doi-asserted-by":"crossref","first-page":"16026","DOI":"10.1074\/jbc.271.27.16026","article-title":"Cellular cholesterol efflux mediated by cyclodextrins: Demonstration of kinetic pools and mechanism of efflux","volume":"271","author":"Yancey","year":"1996","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0350","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/jctb.5912","article-title":"Cross-linked enzyme aggregates of recombinant cyclodextrin glycosyltransferase for high-purity \u03b2-cyclodextrin production","volume":"94","author":"Zhang","year":"2019","journal-title":"Journal of Chemical Technology & Biotechnology"},{"key":"10.1016\/j.pharmthera.2020.107620_bb0355","doi-asserted-by":"crossref","first-page":"333ra50","DOI":"10.1126\/scitranslmed.aad6100","article-title":"Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming","volume":"8","author":"Zimmer","year":"2016","journal-title":"Science Translational Medicine"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820301509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820301509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:07:47Z","timestamp":1759010867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820301509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":72,"alternative-id":["S0163725820301509"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107620","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclodextrins: Potential therapeutics against atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107620"}}